196 related articles for article (PubMed ID: 11801557)
1. Detection of aberrant p16 methylation in the serum of colorectal cancer patients.
Zou HZ; Yu BM; Wang ZW; Sun JY; Cang H; Gao F; Li DH; Zhao R; Feng GG; Yi J
Clin Cancer Res; 2002 Jan; 8(1):188-91. PubMed ID: 11801557
[TBL] [Abstract][Full Text] [Related]
2. p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas.
Wakabayashi T; Natsume A; Hatano H; Fujii M; Shimato S; Ito M; Ohno M; Ito S; Ogura M; Yoshida J
Neurosurgery; 2009 Mar; 64(3):455-61; discussion 461-2. PubMed ID: 19240607
[TBL] [Abstract][Full Text] [Related]
3. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients.
Wong IH; Lo YM; Zhang J; Liew CT; Ng MH; Wong N; Lai PB; Lau WY; Hjelm NM; Johnson PJ
Cancer Res; 1999 Jan; 59(1):71-3. PubMed ID: 9892188
[TBL] [Abstract][Full Text] [Related]
4. p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer.
Bearzatto A; Conte D; Frattini M; Zaffaroni N; Andriani F; Balestra D; Tavecchio L; Daidone MG; Sozzi G
Clin Cancer Res; 2002 Dec; 8(12):3782-7. PubMed ID: 12473590
[TBL] [Abstract][Full Text] [Related]
5. Influence of methylated p15 and p16 genes on clinicopathological features in colorectal cancer.
Ishiguro A; Takahata T; Saito M; Yoshiya G; Tamura Y; Sasaki M; Munakata A
J Gastroenterol Hepatol; 2006 Aug; 21(8):1334-9. PubMed ID: 16872319
[TBL] [Abstract][Full Text] [Related]
6. Methylation of serum DNA is an independent prognostic marker in colorectal cancer.
Wallner M; Herbst A; Behrens A; Crispin A; Stieber P; Göke B; Lamerz R; Kolligs FT
Clin Cancer Res; 2006 Dec; 12(24):7347-52. PubMed ID: 17189406
[TBL] [Abstract][Full Text] [Related]
7. Detection of aberrant methylation as a tumor marker in serum of patients with gastric cancer.
Ichikawa D; Koike H; Ikoma H; Ikoma D; Tani N; Otsuji E; Kitamura K; Yamagishi H
Anticancer Res; 2004; 24(4):2477-81. PubMed ID: 15330201
[TBL] [Abstract][Full Text] [Related]
8. Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma.
Lee TL; Leung WK; Chan MW; Ng EK; Tong JH; Lo KW; Chung SC; Sung JJ; To KF
Clin Cancer Res; 2002 Jun; 8(6):1761-6. PubMed ID: 12060614
[TBL] [Abstract][Full Text] [Related]
9. Detection of aberrant p16 methylation in the serum of colorectal cancer patients.
Zou H; Yu B; Zhao R; Wang Z; Cang H; Li D; Feng G; Yi J
Zhonghua Yu Fang Yi Xue Za Zhi; 2002 Dec; 36(7):499-501. PubMed ID: 12411153
[TBL] [Abstract][Full Text] [Related]
10. Aberrant promoter hypermethylation in serum DNA from patients with silicosis.
Umemura S; Fujimoto N; Hiraki A; Gemba K; Takigawa N; Fujiwara K; Fujii M; Umemura H; Satoh M; Tabata M; Ueoka H; Kiura K; Kishimoto T; Tanimoto M
Carcinogenesis; 2008 Sep; 29(9):1845-9. PubMed ID: 18632757
[TBL] [Abstract][Full Text] [Related]
11. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer.
Hoque MO; Begum S; Topaloglu O; Jeronimo C; Mambo E; Westra WH; Califano JA; Sidransky D
Cancer Res; 2004 Aug; 64(15):5511-7. PubMed ID: 15289362
[TBL] [Abstract][Full Text] [Related]
12. p16INK4a methylation in serum as a follow-up marker for recurrence of colorectal cancer.
Nakayama G; Kodera Y; Ohashi N; Koike M; Fujiwara M; Nakao A
Anticancer Res; 2011 May; 31(5):1643-6. PubMed ID: 21617221
[TBL] [Abstract][Full Text] [Related]
13. A highly sensitive method for the detection of p16 methylation in the serum of colorectal cancer patients.
Nakayama G; Hibi K; Nakayama H; Kodera Y; Ito K; Akiyama S; Nakao A
Anticancer Res; 2007; 27(3B):1459-63. PubMed ID: 17595762
[TBL] [Abstract][Full Text] [Related]
14. The potential prognostic, predictive, and therapeutic values of DNA methylation in cancer. Commentary re: J. Kwong et al., Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin. Cancer Res., 8: 131-137, 2002, and H-Z. Zou et al., Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin. Cancer Res., 8: 188-191, 2002.
Widschwendter M; Jones PA
Clin Cancer Res; 2002 Jan; 8(1):17-21. PubMed ID: 11801535
[No Abstract] [Full Text] [Related]
15. Aberrant methylation of the p16 gene is frequently detected in advanced colorectal cancer.
Goto T; Mizukami H; Shirahata A; Sakata M; Saito M; Ishibashi K; Kigawa G; Nemoto H; Sanada Y; Hibi K
Anticancer Res; 2009 Jan; 29(1):275-7. PubMed ID: 19331161
[TBL] [Abstract][Full Text] [Related]
16. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer.
Kawamoto K; Enokida H; Gotanda T; Kubo H; Nishiyama K; Kawahara M; Nakagawa M
Biochem Biophys Res Commun; 2006 Jan; 339(3):790-6. PubMed ID: 16316628
[TBL] [Abstract][Full Text] [Related]
17. Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients.
Sharma G; Mirza S; Prasad CP; Srivastava A; Gupta SD; Ralhan R
Life Sci; 2007 Apr; 80(20):1873-81. PubMed ID: 17383681
[TBL] [Abstract][Full Text] [Related]
18. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer.
Fujiwara K; Fujimoto N; Tabata M; Nishii K; Matsuo K; Hotta K; Kozuki T; Aoe M; Kiura K; Ueoka H; Tanimoto M
Clin Cancer Res; 2005 Feb; 11(3):1219-25. PubMed ID: 15709192
[TBL] [Abstract][Full Text] [Related]
19. [Detection of free tumor-related DNA in the serum of breast cancer patients].
Zhang JJ; Ouyang T; Wan WH; Deng GR
Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):609-13. PubMed ID: 18210882
[TBL] [Abstract][Full Text] [Related]
20. Tumor-derived aberrant methylation in plasma of invasive ductal breast cancer patients: clinical implications.
Hu XC; Wong IH; Chow LW
Oncol Rep; 2003; 10(6):1811-5. PubMed ID: 14534701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
